Emerging research suggests that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), while primarily used to treat hypertension and heart failure, may also benefit OA patients by modulating the renin-angiotensin-aldosterone system (RAAS) [116]. The gene discussed is ACE; the disease is hypertensive disorder.